CEO

Dr. Vleugels received MA in Economics (University of Texas at Austin, 1984) and completed his PhD in Policy Sciences at Radboud University Nijmegen in 1990. He worked as technology transfer officer for the Medical Faculty of the Maastricht University, where he was one of the founders of the Biopartner valorization programme to generate start-up companies. In 1996, Dr. Vleugels founded MUbio Products with Prof. Frans Ramaekers. Dr. Vleugels was the managing director till 2010. He also founded NovoVacs which merged with MUbio in 2006. In 2012, Dr. Vleugels co-founded CyTuVax with Prof. Frank Falkenberg.

Scientific Director

Professor Falkenberg holds German and international patents in the fields of bioreactor technology, tumor immunology and nephrotoxicity testing. In 2001 he founded CIRES: Cell & Immune Research Services GmbH, a biotech contract research company in Dortmund. In 2011 he co-founded CyTuVax.

Professor Falkenberg received his MSc in Biochemistry at the J.W. Goethe Universität in Frankfurt/Main and his PhD in Biochemistry at the Department of Biochemistry (Faculty of Chemistry) of the Ruhr-Universität Bochum. He was Postdoc fellow at the Department of Chemical Immunology of the Weizmann Institute of Science in Rehovot, Israel from 1971 – 1973. In 1981, he was privat lecturer at the Department of Medical Microbiology, Medical Faculty of the Ruhr-Universität Bochum. In 1986 he became Professor of Immunology in the Medical Faculty of the Ruhr-Universität Bochum.

Prof Falkenberg’s main scientific interests are immunogenetics, cellular immunology, tumor immunology, cell culture, and bioreactor technology. For the last 15 years, Prof. Falkenberg’s main work was to develop the CyTuVax’s adjuvant platform technology.

Commercial & Financial Officer

Received a M.Sc. in Business Administration at the University of Groningen (1993). Acquired “hands on” global pharmaceutical industry experience in the 3 key markets (US, Japan and Europe) in increasingly senior operations, sales, marketing, finance and general management positions. Both at national as well as regional level, initially at Organon (1993 – 2007) followed by Schering-Plough (2007-2008) and in most recent years with AstraZeneca (2009-2017). Joined CyTuVax as Commercial & Financial Officer in September 2017 in order to secure future funding and to prepare next steps beyond the on-going phase II study for Hepatitis B vaccination in non-responders. At the same time expanding the opportunities with the proprietary platform technology both in the prophylactic as well as the therapeutic application.

Senior Scientist - Clinical Research Coordinator

Dr. Almeida is bioscientist who was trained in Biology, Microbiology, and Genetics at University of Lisbon in 2005. He obtained his PhD in Immunology at University Pierre et Marie Curie in Paris 2009. After that, Dr. Almeida worked as Postdoc with the National Institutes of Health in Maryland, USA from 2009 to 2013. Since 2014 he is our Senior Scientist at CyTuVax.

Currently, Dr. Almeida is leading the clinical development and coordination of the Phase-2 clinical trial of HBAI20 - Adjuvant-enhanced hepatitis B vaccine for non-responders.

Ms Katharina received a B.Sc degree in the department of Geo-Botanics of Bochum University. Her master thesis (Studies on the cellular and molecular processes involved in the vaccination with cytokine depot vaccines) was done at CIRES. She received a MS.c in the Faculty of Biology and Biotechnology of the Ruhr-Universitaet Bochum in 2013. Since 2014 She is Research Scientist at CIRES.